Spark Therapeutics, a Roche company, has officially started work on its US$575m gene therapy innovation center in West Philadelphia. The center is expected to be completed by 2026.
Roche’s acquisition of Spark was announced at the start of the year but closing the deal has proved difficult after a third delay incurred to give the FTC extra review time.